Effect of Rifampin and Rifabutin on the Pharmacokinetics of Lersivirine and Effect of Lersivirine on the Pharmacokinetics of Rifabutin and 25-O-Desacetyl-Rifabutin in Healthy Subjects

The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects

(2012) John Davis et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

HIV-1/Mycobacterium tuberculosisCoinfection Immunology: How Does HIV-1 Exacerbate Tuberculosis?

(2011) Collin R. Diedrich et al.   INFECTION AND IMMUNITY

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

(2010) Awewura Kwara et al.   AIDS

Decreased plasma efavirenz concentrations in a patient receiving rifabutin

(2010) O. Hsu et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

(2010) R. Corbau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs

(2010) Thomas N. Kakuda et al.   CLINICAL PHARMACOKINETICS

Excretion and Metabolism of Lersivirine (5- benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers

(2010) M. Vourvahis et al.   DRUG METABOLISM AND DISPOSITION

Emerging antiretroviral drug interactions

(2010) P. A. Pham et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients

(2009) Gerd Fätkenheuer et al.   AIDS

CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India

(2009) G. Ramachandran et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis

(2009) Yuan Ren et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect ofCYP2B6Variation

(2008) Awewura Kwara et al.   JOURNAL OF CLINICAL PHARMACOLOGY